Home Tags EpiPen
Ten years ago, I testified before Congress about drug pricing — and it’s only gotten worse. Here’s what’s wrong, and how we ma...
Jasmin Weaved testified in front of Congress about "out of control" pricing for prescription drugs, but not much has changed.
In June, the Food and Drug Administration extended the expiration date on some EpiPens to help with a shortage of the devices.
Welcome to Dispensed, Business Insider's weekly newsletter giving you a dose of pharma, biotech, and healthcare news.
People rely on the EpiPen in life-or-death situations, but the devices are remarkably hard to test. Here’s why.
Testing lifesaving EpiPens before they get to patients is challenging because testing destroys them, according to the EpiPen's manufacturer.
EpiPens weren’t working. It took 3 years and the FDA stepping in before serious change — with potentially deadly outcomes
Consumer complaints about EpiPens were increasing, but its manufacturer wasn’t properly looking into those complaints, FDA inspectors warned in 2014.
Drug giant Novartis is gearing up to release a cheaper EpiPen rival, but one big factor may make competition tricky
The Thursday announcement shows an end in sight for the 17-month saga that has stretched since Symjepi was first approved by U.S. regulators.
The strange history of the EpiPen, the device developed by the military that turned into a billion-dollar business and now faces generic competition b...
Here's the story of how a common, lifesaving device became a controversial drug-pricing story, facing recalls, shortages, and now generic competition between Mylan and Teva.
Mylan stock dropped over 7% after it released its second quarter earning report. The company then announced that it was to undergo a strategic review.
The FDA on Wednesdsay said that there's a shortage of EpiPens in the US. Mylan, the company that distributes the emergency allergy medication, said that there are "intermittent supply constraints," but supply is available.
Mylan’s shareholders just voted against its executive pay, which included a $100 million package for its chairman
Mylan shareholders voted to re-elect the generic drugmaker's board at its annual meeting on Thursday, despite a push to to vote down most of the directors.